Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 0.74 |
| ▸ | NOS1 | P29475 | 9/20 | 0.55 |
| ▸ | NOS3 | P29474 | 9/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1188222 | 0.93 | NOS2 (0.66) | NOS2NOS1NOS3KCNH2ESR1 | |
| SCHEMBL1187329 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 | |
| SCHEMBL1188113 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 | |
| SCHEMBL1188072 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 | |
| SCHEMBL1187021 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 | |
| SCHEMBL1187601 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 | |
| SCHEMBL1187537 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 | |
| SCHEMBL1187340 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 | |
| SCHEMBL1188212 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 | |
| SCHEMBL1188068 | 0.91 | NOS2 (0.63) | NOS2NOS1NOS3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1982988-B1 | METHOD OF SYNTHESIS OF CIGUATOXIN CTX1B AND COMPOUNDS USEFUL FOR THE SYNTHESIS OF CIGUATOXIN CTX1B | JAPAN SCIENCE & TECH AGENCY (JP) | 2014-06-04 | — | — | EP | claimed |
| US-20100160651-A1 | METHOD FOR SYNTHESIS OF CIGUATOXIN CTX1B AND COMPOUNDS USEFUL FOR THE SYNTHESIS OF CIGUATOXIN CTX1B | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-06-24 | — | — | US | claimed |
| EP-1982988-A1 | METHOD FOR SYNTHESIS OF CIGUATOXIN CTX1B AND COMPOUND USEFUL FOR THE SYNTHESIS OF CIGUATOXIN CTX1B | Japan Science and Technology Agency (JP) | 2008-10-22 | — | — | EP | claimed |
| EP-4644396-A1 | TOLL-LIKE RECEPTOR INHIBITOR, AND PREPARATION THEREFOR AND APPLICATION THEREOF | Visionpharma (Nantong) Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
| CN-106957400-A | A kind of soft segment is isobutene, and hard section is the preparation method of the special elastomer of Styrene and its derivatives | 北京石油化工学院 | 2017-07-18 | — | — | CN | disclosed |
| US-20150374840-A1 | MODIFIED PEPTIDES AND PROTEINS | AmideBio LLC | 2015-12-31 | — | — | US | disclosed |
| EP-2846798-A2 | ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-1982988-B1 | METHOD OF SYNTHESIS OF CIGUATOXIN CTX1B AND COMPOUNDS USEFUL FOR THE SYNTHESIS OF CIGUATOXIN CTX1B | JAPAN SCIENCE & TECH AGENCY (JP) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013169574-A2 | ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| EP-1843407-A1 | Liquid crystalline rylenetetracarboxylic acid derivatives and their use | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20050107622-A1 | Novel method for wholly synthesizing of ciguatoxin ctx3c derivative | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1268502-A1 | O-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074834-A1 | O-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2000064908-A1 | N-TRI OR DI-ALKYLSILYL( PERFLUOROAL KANESULPHONYL) IMIDE DERIVATIVES, PREPARATION AND USE | RHODIA CHIMIE (FR) | 2000-11-02 | — | — | WO | disclosed |
| WO-1998016528-A1 | PURINE INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 (GSK3) | CHIRON CORPORATION (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5618807-A | Method for preparing 17-substituted steroids useful in cancer treatment | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-04-08 | — | — | US | disclosed |
| EP-0740657-A1 | 4-ARYLISOINDOLE ANALGESICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995017384-A1 | 4-ARYLISOINDOLE ANALGESICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160651-A1 | METHOD FOR SYNTHESIS OF CIGUATOXIN CTX1B AND COMPOUNDS USEFUL FOR THE SYNTHESIS OF CIGUATOXIN CTX1B | CBR3, ADCY6, ADCY3 | NOS2 3415/4885NOS1 3010/4885NOS3 1738/4885 |
| US-20150374840-A1 | MODIFIED PEPTIDES AND PROTEINS | IAPP, VIP, ENPEP | NOS2 2390/4885NOS1 2239/4885NOS3 2027/4885 |
| US-20050107622-A1 | Novel method for wholly synthesizing of ciguatoxin ctx3c derivative | PRXL2A, CNPY3, PRDX6 | NOS2 952/4885NOS1 1285/4885NOS3 192/4885 |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | NOS2 3930/4885NOS1 3795/4885NOS3 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.